Diabetes, Vol 37, Issue 5 577-584, Copyright © 1988 by American Diabetes Association

ARTICLES

Composition changes in hepatic microsomal cytochrome P-450 during onset of streptozocin-induced diabetes and during insulin treatment

LV Favreau and JB Schenkman
Department of Pharmacology, University of Connecticut Health Center, Farmington 06032.

Monospecific polyclonal antibodies to five constitutive hepatic microsomal cytochromes P-450 were prepared. These antibodies were used to monitor alterations in the content of the enzymes in livers of diabetic male rats. Within 3 wk of onset of streptozocin-induced diabetes, immunodetectable levels of RLM3 and RLM5 were decreased by 85 and greater than 95%, respectively. Insulin treatment for 1 wk reversed the decline in these isozymes and restored RLM3 to 60% and RLM5 to 53% of levels found in the untreated rat. After a 2nd wk of therapy, these levels were returned to 86 and 92%, respectively. In contrast, the levels of RLM5b and RLM6 were elevated in diabetes 1.7- and 8-fold, respectively. Insulin treatment for 1 wk only slightly decreased the levels of RLM5b but completely reduced RLM6 levels to those seen in age-matched untreated rats. After the 2nd wk of insulin treatment, the level of RLM5b was almost completely restored to normal, with no additional change in the RLM6 level. The level of a fifth enzyme, RLM5a, was not markedly altered by diabetes or by insulin treatment. The results suggest there are at least three types of responses by constituents of the cytochrome P-450 population to diabetes: no change in the microsomal content, a rapid increase when insulin level declines and restoration when insulin is supplied, and a rapid decline when insulin level declines and a restoration by insulin treatment.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. Sugatani, T. Wada, M. Osabe, K. Yamakawa, K. Yoshinari, and M. Miwa Dietary Inulin Alleviates Hepatic Steatosis and Xenobiotics-Induced Liver Injury in Rats Fed a High-Fat and High-Sucrose Diet: Association with the Suppression of Hepatic Cytochrome P450 and Hepatocyte Nuclear Factor 4{alpha} Expression Drug Metab. Dispos., October 1, 2006; 34(10): 1677 - 1687. [Abstract] [Full Text] [PDF]

				G. J. Pass, W. Becker, R. Kluge, K. Linnartz, L. Plum, K. Giesen, and H.-G. Joost Effect of Hyperinsulinemia and Type 2 Diabetes-Like Hyperglycemia on Expression of Hepatic Cytochrome P450 and Glutathione S-Transferase Isoforms in a New Zealand Obese-Derived Mouse Backcross Population J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 442 - 450. [Abstract] [Full Text] [PDF]

				T. Wang, K. Shankar, M. J. J. Ronis, and H. M. Mehendale Potentiation of Thioacetamide Liver Injury in Diabetic Rats Is Due to Induced CYP2E1 J. Pharmacol. Exp. Ther., August 1, 2000; 294(2): 473 - 479. [Abstract] [Full Text]

				K. J. Woodcroft and R. F. Novak Insulin Differentially Affects Xenobiotic-Enhanced, Cytochrome P-450 (CYP)2E1, CYP2B, CYP3A, and CYP4A Expression in Primary Cultured Rat Hepatocytes J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 1121 - 1127. [Abstract] [Full Text]

				E. T. Morgan, M. B. Sewer, H. Iber, F. J. Gonzalez, Y.-H. Lee, R. H. Tukey, S. Okino, T. Vu, Y.-H. Chen, J. S. Sidhu, et al. Physiological and Pathophysiological Regulation of Cytochrome P450 Drug Metab. Dispos., December 1, 1998; 26(12): 1232 - 1240. [Abstract] [Full Text]

				C. Courteix, P. Bourget, F. Caussade, M. Bardin, F. Coudore, J. Fialip, and A. Eschalier Is the Reduced Efficacy of Morphine in Diabetic Rats Caused by Alterations of Opiate Receptors or of Morphine Pharmacokinetics? J. Pharmacol. Exp. Ther., April 1, 1998; 285(1): 63 - 70. [Abstract] [Full Text]

				Y.-J. Liu, Y. Nakagawa, and T. Ohzeki Gene Expression of 11ß-Hydroxysteroid Dehydrogenase Type 1 and Type 2 in the Kidneys of Insulin-Dependent Diabetic Rats Hypertension, March 1, 1998; 31(3): 885 - 889. [Abstract] [Full Text] [PDF]